These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1968963)

  • 1. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
    Coleman RJ; Quinn NP; Traub M; Marsden CD
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
    Coleman RJ; Lange KW; Quinn NP; Loper AE; Bondi JV; Hichens M; Stahl SM; Marsden CD
    Mov Disord; 1989; 4(2):129-38. PubMed ID: 2733705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
    Cedarbaum JM; Clark M; Toy LH; Green-Parsons A
    Mov Disord; 1990; 5(4):298-303. PubMed ID: 1979657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
    Weiner WJ; Factor SA; Sanchez-Ramos JR
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.
    Muenter MD; Ahlskog JE; Bell G; McManis P
    Neurology; 1988 Oct; 38(10):1541-5. PubMed ID: 2901697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiparkinsonian activity of a single oral dose of PHNO.
    Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
    Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
    Grandas Perez FJ; Jenner PG; Nomoto M; Stahl S; Quinn NP; Parkes JD; Critchley P; Marsden CD
    Lancet; 1986 Apr; 1(8486):906. PubMed ID: 2870368
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
    Cedarbaum JM; Silvestri M; Kutt H
    Neurology; 1990 Jun; 40(6):995-7. PubMed ID: 2345621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
    Lieberman A; Chin L; Baumann G
    Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
    Ahlskog JE; Muenter MD; Bailey PA; Miller PM
    Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
    de Yebenes JG; Fahn S; Jackson-Lewis V; Mena MA
    Mov Disord; 1987; 2(4):291-9. PubMed ID: 2904650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.
    Stoessl AJ; Mak E; Calne DB
    Lancet; 1985 Dec; 2(8468):1330-1. PubMed ID: 2866388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 17. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Schelosky L; Poewe W
    Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.